



Canadian Agency for
Drugs and Technologies
in Health

RAPID RESPONSE REPORT: SUMMARY WITH CRITICAL APPRAISAL



TITLE: Stool Antigen Tests for *Helicobacter pylori* Infection: A Review of Clinical and Cost-Effectiveness and Guidelines

DATE: 08 January 2015

CONTEXT AND POLICY ISSUES

Helicobacter pylori (*H. pylori*) is Gram negative bacillus that colonizes the mucus layer of the human stomach and the upper part of small intestine (duodenum).^{1,2} It is the principal cause of peptic ulcer disease and the main risk of gastric cancer.² Most infected individuals (> 70%) are asymptomatic.² The rates of *H. pylori* infection increase with age. In Canada, one in five people age 30 years old (about one million) is infected.¹ The rate increases to one in every two people aged 80 years or older (0.5 million).¹ About 75% of the people in First Nation communities are infected with *H. pylori*.¹ Based on origin of birth and/or area of residence, there are approximately over 4 million Canadians who are considered to be at high risk for *H. pylori* infection; total cost of testing and eradication for those people are estimated to be \$350 million.¹

H. pylori can be detected by invasive or non-invasive tests.³ Endoscopic examination of the stomach and duodenum followed by removal of biopsy samples is an invasive procedure.³ Tests such as histology, rapid urease testing, culture, or polymerase chain reaction (PCR) have been widely used to detect of *H. pylori* from the biopsy samples.³ Urea breath tests, stool antigen tests, and serology are the non-invasive tests.³

There are two types of stool antigen tests for the diagnosis of *H. pylori* infection, one based on enzyme immunoassay (EIA) and the other based on immunochromatography (ICA).⁴ Both types of tests can be operated using either monoclonal antibody or polyclonal antibodies.⁴ Although both are highly sensitive and specific, the EIA-based tests appears to be more accurate than the ICA-based tests.^{4,5} However, the ICA-based tests do not required specialized equipment, are easy to use, and are useful for rapid diagnosis of *H. pylori* infection.⁴

The aim of this report is to review the diagnostic accuracy, clinical effectiveness, cost-effectiveness, and guidelines of stool antigen tests for *H. pylori* infection.

RESEARCH QUESTIONS

1. What is the diagnostic accuracy and clinical effectiveness of stool antigen tests in patients with suspected *H. pylori* infections?

Disclaimer: The Rapid Response Service is an information service for those involved in planning and providing health care in Canada. Rapid responses are based on a limited literature search and are not comprehensive, systematic reviews. The intent is to provide a list of sources and a summary of the best evidence on the topic that CADTH could identify using all reasonable efforts within the time allowed. Rapid responses should be considered along with other types of information and health care considerations. The information included in this response is not intended to replace professional medical advice, nor should it be construed as a recommendation for or against the use of a particular health technology. Readers are also cautioned that a lack of good quality evidence does not necessarily mean a lack of effectiveness particularly in the case of new and emerging health technologies, for which little information can be found, but which may in future prove to be effective. While CADTH has taken care in the preparation of the report to ensure that its contents are accurate, complete and up to date, CADTH does not make any guarantee to that effect. CADTH is not liable for any loss or damages resulting from use of the information in the report.

Copyright: This report contains CADTH copyright material. It may be copied and used for non-commercial purposes, provided that attribution is given to CADTH.

Links: This report may contain links to other information available on the websites of third parties on the Internet. CADTH does not have control over the content of such sites. Use of third party sites is governed by the owners' own terms and conditions.

2. What is the cost-effectiveness of stool antigen tests in patients with suspected *H. pylori* infections?
3. What are the evidence-based guidelines associated with stool antigen tests in patients with suspected *H. pylori* infections?

KEY FINDINGS

Certain commercially available stool antigen tests with high test performance (sensitivity and specificity) provide reliable results in the diagnosis of *H. pylori* infection and in follow-up testing after eradication therapy. The use of a stool antigen test-and-treat strategy in relieving symptoms of dyspepsia or reducing the burden of gastric cancer and peptic ulceration was cost-effective. Guidelines recommend a laboratory-based validated monoclonal stool test for test-and-treat strategies and for follow-up testing after eradication therapy.

METHODS

Literature Search Strategy

A limited literature search was conducted on key resources including PubMed, The Cochrane Library (2014, Issue 12), University of York Centre for Reviews and Dissemination (CRD) databases, Canadian and major international health technology agencies, as well as a focused Internet search. No filters were applied to limit the retrieval by study type. Where possible, retrieval was limited to the human population. The search was also limited to English language documents published between January 1, 2009 and December 3, 2014.

Selection Criteria and Methods

One reviewer screened the titles and abstracts of the retrieved publications and evaluated the full-text publications for the final article selection, according to selection criteria presented in Table 1.

Table 1: Selection Criteria	
Population	Adult patients with suspected <i>Helicobacter pylori</i> infection
Intervention	Stool antigen tests (other names may be fecal testing for <i>H. pylori</i> , fecal testing, fecal calprotectin assay)
Comparator	Endoscopy/biopsy procedure Carbon-13 urea breath test
Outcomes	<ul style="list-style-type: none"> • Clinical effectiveness and diagnostic accuracy (accuracy, clinical benefit, patient harms, safety); including comparative clinical effectiveness with other procedures. • Cost-effectiveness (e.g. cost of tests, travel associated with testing), including comparative cost-effectiveness with other procedures. • Guidelines
Study Designs	Health technology assessments, systematic reviews, meta-analyses, randomized controlled trials, non-randomized studies, economic evaluations, and guidelines

Exclusion Criteria

Studies were excluded if they did not satisfy the selection criteria in Table 1, if they were published prior to 2009, duplicate publications of the same study, or included in a selected health technology assessment or systematic review.

Critical Appraisal of Individual Studies

For the critical appraisal of studies, a numeric score was not calculated. Instead, the strength and limitations of the studies were described.

The quality of diagnostic studies was assessed using QUADAS-2.⁶ Economic studies were assessed for completeness of reporting of the model, model inputs, data sources, and disaggregated results, and the sensitivity analyses conducted, based on the British Medical Journal Checklist for economic studies.⁷ The Appraisal of Guidelines Research & Evaluation (AGREE II) instrument was used to evaluate the quality of the included guidelines.⁸

SUMMARY OF EVIDENCE

Quantity of Research Available

The literature search yielded 239 citations. Upon screening titles and abstracts, 32 potential relevant articles were retrieved for full-text review. Four additional relevant reports were retrieved from other sources. Of the 36 potentially relevant articles, 24 reports were included in this review including 21 diagnostic studies,⁹⁻²⁹ two economic studies^{30,31} and one guideline.³² No health technology assessments, systematic reviews, meta-analyses, and randomized controlled trials on the clinical effectiveness of stool antigen tests could be identified. The study selection process is outlined in a PRISMA flowchart (Appendix 1).

Summary of Study Characteristics

The characteristics of the diagnostic studies and economic studies are summarized in Appendix 2 and 3, respectively. Appendix 4 presents the grading of recommendations and levels of evidence of the included guidelines.

Of the 21 diagnostic studies of fecal antigen in the stool, 15 studies⁹⁻²³ were for diagnosis of suspected patients with *H. pylori* infection and six studies²⁴⁻²⁹ were for follow-up testing after patients receiving *H. pylori* eradication therapy. Most studies were prospective and included patients suffering from gastrointestinal disorders including dyspeptic symptoms, who were referred to hospital for upper gastrointestinal endoscopy examination. Two studies included hemodialysis patients.^{16,26} The stool antigen tests were commercially available from different manufacturers and were of different types. These included EIA-based tests using monoclonal antibody,^{9,12-17,21,23-25,27-29} EIA-based tests using polyclonal antibodies,^{11,19,26,29} ICA-based tests using a monoclonal antibody,^{10,13,18,20,25} and ICA-based tests using polyclonal antibodies.^{13,21} For EIA based tests, the cut-off value was not reported in many studies, likely because it was present in the manufacturers' instructions. Gold standard tests varied among studies and consisted of either a single test, typically one of the invasive tests using biopsy specimens from endoscopy (culture, PCR, histopathology, or rapid urease test), or a combination of invasive tests and non-invasive tests such as the urea breath test, serology, or stool antigen test. The test performance outcomes included sensitivity, specificity, positive predictive value, negative predictive value and accuracy. For follow-up studies after *H. pylori* eradication therapy, the percentage of agreement between the stool antigen test and urea breath test was also reported, as the latter is the indicated test for follow-up.

The economic study by Schulz et al. (2014)³¹ investigated which of the nine different screening and follow-up strategies would be cost effective in asymptomatic immigrants and refugees, which are high *H. pylori* prevalence populations. Screening tests included serology, stool antigen, urea breath test, and endoscopy (gastroscopy). The prevalence of *H. pylori* was assumed to be 25%, 50% or 75%. The primary outcome, which was the net cost for each cancer prevented for each strategy per 1000 people, was calculated using a decision analytic model. Costs and treatment efficacy were based on published estimates. A sensitivity analysis was performed on the most cost effective strategy in the initial analysis (stool testing with retesting of those treated). The parameters tested were cost of managing one cancer, cost of a physician visit, cost of medication for eradication, cost of managing one peptic ulcer and lifetime risk of gastric cancer. The payer perspective was taken. The time horizon of costs was the patient's life time. Costs were in 2011 US dollars. There was no discounting rate. The population included immigrants and refugees from developing countries.

The economic study by Holmes et al. (2010)³⁰ compared the cost-effectiveness of various, non-invasive testing strategies of *H. pylori* infection including stool antigen testing, IgG serology, IgG serology with reflex to stool antigen, urea breath testing, and IgG/IgA binary serology. The primary outcome, which was cost per symptom-free year, was calculated using a Markov simulation model. The cost per correct diagnosis was also reported as an outcome. Uncertainty of outcomes was estimated using probabilistic sensitivity analysis by changing the prevalence of *H. pylori* (5% to 40%). The societal perspective was taken. The time horizon of costs was the patient's life time. Costs were in 2009 US dollars. There was no discounting rate. The population included dyspeptic patients (< 55 years of age) with the possibility of having *H. pylori* infection, peptic ulcer(s), or both. Patients would begin to receive each of the first five tests; if positive, they would receive triple therapy (clarithromycin, amoxicillin, and lansoprazole); if negative, they would have proton pump inhibitor (PPI) therapy. If there was no relief of symptoms after initial management, or if symptoms recurred, patients would go on to receive an endoscopy with biopsy. Baseline costs of tests and treatments were based on 2009 national midpoint Medicare reimbursement rates. A probabilistic sensitivity analysis was undertaken by simulating 250 trials involving 10,000 patients each. Incremental cost-effectiveness ratios (ICERs) were calculated based on a single simulated cohort of 500,000 patients using empiric PPI trial data (i.e., no testing) as the baseline for comparison.

The European guideline on the management of *H. pylori* infection was published in 2012.³² The guidelines were developed by a panel of 44 experts from 24 countries that convened in Florence in 2010. The goal of the guidelines was to provide recommendations to health care practitioners for clinical management of *H. pylori* infection, focussing on indications, diagnostic and treatments of *H. pylori* infection with additional emphasis on disease prevention – in particular, prevention of gastric cancer. Recommendations were graded according to the strength of the recommendation and quality of the supporting evidence (Appendix 4). Consensus was defined as support by at least 70% of the experts.

Summary of Critical Appraisal

The strengths and limitations of diagnostic studies, economic studies and guidelines are summarized in Appendix 5, 6 and 7, respectively.

QUADAS-2 was used to assess the quality of the diagnostic studies. The instrument consists of four domains. Domain 1 has three questions dealing with method of patient selection. Domain 2 has two questions dealing with the conduct and interpretation of the index test(s). Domain 3 has two questions dealing with the conduct and interpretation of the standard test. Domain 4 has four questions asking if there is an appropriate time interval and interventions between index

test(s) and standard test, and whether all patients receive index test(s) and/or reference standard. Overall, for Domain 1, the risk of bias (including consecutive or random sample of patients were enrolled, and the avoiding of case-control design and inappropriate exclusions) in all studies, except three,^{11,12,20} was low. The risk of bias for Domain 1 was high in one study¹¹ since up to 63% of patients were excluded from the study, and it was unclear in two studies^{12,20} as it was unclear if the studies avoided inappropriate exclusions. For Domain 2, all studies had low risk of bias (i.e., the index test results were interpreted without knowledge of the results of the reference standard and a threshold used was pre-specified). For Domain 3, it was unclear if the reference standard test correctly classified the target condition in 10 studies,^{9,10,16,22,24-29} while the risk of bias in the rest of the studies was low (i.e., the reference standard was likely to correctly classify the target condition, and the reference standard results were interpreted without the results of the index test).^{11-15,17-21,23} Although in some studies^{16,20,23} the stool antigen test may have been part of the reference standard panel of tests. For Domain 4, the risk of bias was high in four studies^{9,11,12,25} as not all patients received index test(s) and/or the reference standard test. The timing between index test(s) and reference standard was unclear in all studies, meaning that it is possible that there were changes in condition or health status between tests.

The economic study by Schulz et al. (2014)³¹ was generally well conducted and had considerable strengths in study design, data collection, and analysis and interpretation of results based on British Medical Journal Checklist for economic studies (Appendix 6). However, the discount rate and details of statistical tests were not given in this study. The study by Holmes et al. (2010)³⁰ had several limitations in data collection and analysis and interpretation of results including the lack of methods to value benefit, quantities of resource used, price adjustments, discount rate, the choice of variable for sensitivity analysis and details of statistic tests.

The included guideline³² was explicit in scope and purpose, stakeholder involvement, rigour of development (except a method for guideline updating), clarity of recommendation according to AGREE II instrument (Appendix 7). Limitations of this guideline rested mainly on the applicability, for example, there was no description of facilitators and barriers to its application, and lack of advice and/or tools on how the recommendations can be put into practice.

Summary of Findings

The main findings of fecal antigen detection studies and economic studies are presented in Appendix 8 and 9, respectively. The guideline's recommendations on stool antigen tests for *H. pylori* infection are shown in Appendix 10.

A. Fecal antigen detection studies (for diagnosis)

Table 2 summarizes the test performance results of different commercially available kits used for diagnosis of *H. pylori* infection. The sensitivity and specificity values varied substantially depending on the test kit and the reference standard used, assuming errors in the handling and preparation of samples were negligible.

- Among the EIA-based tests using monoclonal antibody, the Testmate pylori antigen (TPAg EIA),⁹ Premier Platinum HpSA,^{13,21} and Amplified IDEIA Hp Star²³ using the corresponding reference standards had better test performance compared to other EIA-based tests. Sensitivity of those tests ranged from 90.0% to 92.4%, and specificity ranged from 91.0% to 100%.
- Among the two EIA-based tests using polyclonal antibodies, the EZ-STEP *H. pylori*¹⁹ was the preferred test kit (sensitivity: 93.1%; specificity: 94.6%), though it is important to

note that these were compared to different reference standards and may have been subject to different sample preparation and handling.

- Among the ICA-based tests using monoclonal antibody, the Atlas *H. pylori* antigen test¹⁰ had highest test performance (sensitivity: 91.7%; specificity: 100%).
- Both ICA-based tests using polyclonal antibodies had sensitivity and specificity over 80% (sensitivity: 81.0%, 86.7%; specificity: 88.9%, 92.0%).^{13,21}

Table 2: Test Performance Results of Different Stool Antigen Test Kits Used for Diagnosis of *H. pylori* Infection

Stool antigen test kit	Reference standard	Sensitivity (%)	Specificity (%)
EIA-based (monoclonal)			
Testmate pylori antigen (TPAg EIA) ⁹	Stool PCR	92.4	100
Premier Platinum HpSA ¹³	Endoscopy (histopathology and rapid urease test)	92.2	94.4
Premier Platinum HpSA ²¹	Endoscopy (histopathology and rapid urease test)	90.0	91.0
Amplified IDEIA Hp Star ²³	At least two of four tests (histopathology, rapid urease test, urea breath test, and fecal test) were positive	90.3	93.0
Amplified IDEIA Hp Star ¹²	Two positive tests: gastric biopsy plus one of urease, breath or serology	87.2	44.0
HP Ag ¹³	Endoscopy (histopathology and rapid urease test)	48.9	88.9
HP Ag ²¹	Endoscopy (histopathology and rapid urease test)	77.0	91.0
Test kit from ASTRA ¹⁴	Positive: by PCR on biopsy; Negative: by all invasive tests	87.8	75.0
HpSA ¹⁵	Endoscopy (histopathology using hematoxylin and eosin and modified giemsa)	66.0	91.0
HpSA ¹⁶	At least two out of three tests (urea breath test, stool antigen test and serology) were positive	100	75.0
Femtolab <i>H. pylori</i> Cnx ¹⁷	Endoscopy (histopathology using giemsa, and hematoxylin and eosin)	72.2	66.7
EIA-based (polyclonal)			
ELISA kit Immunodagnostik AG ¹¹	Endoscopy (histopathology using Giemsa stain)	72.2	Not determined
EZ-STEP <i>H. pylori</i> ¹⁹	At least two of four tests (histology, rapid urease test, urea breath test, and serology) were positive	93.1	94.6
ICA-based (monoclonal)			
Atlas <i>H. pylori</i> antigen test ¹⁰	Endoscopy (rapid urease test)	91.7	100
ImmonoCard STAT! ¹³	Endoscopy (histopathology and rapid urease test)	68.9	92.6
<i>H. pylori</i> fecal antigen ¹³	Endoscopy (histopathology and rapid urease test)	78.9	87.0
Helicobacter antigen	Endoscopy (histopathology)	68.9	100

Stool antigen test kit	Reference standard	Sensitivity (%)	Specificity (%)
Quick Castle ¹⁸			
Kits from GENERIC ASSAYS GmbH ²⁰	At least two of five tests (stool antigen test, urea breath test, rapid urease test, serology and histology) were positive	96.0	83.0
IHP-602 from ACON ²²	Urea breath test	88.0	87.5
ICA-based (polyclonal)			
One-step <i>H. pylori</i> antigen ¹³	Endoscopy (histopathology and rapid urease test)	86.7	88.9
Kits from Vegal Farmaceutical ²¹	Endoscopy (histopathology and rapid urease test)	81.0	92.0

B. Fecal antigen detection studies (for follow-up testing)

Table 3 summarizes the test performance results of different commercially available kits used for follow-up testing.

Five studies of EIA-based tests using monoclonal antibody^{24,25,27-29} found that the stool antigen tests were accurate and useful tool to determine the results of *H. pylori* eradication therapy compared to endoscopy (histopathology) and/or urea breast test. The EIA-based tests using polyclonal antibodies^{26,29} had high specificity (93.3%, 97.5%), but low sensitivity (42.8%, 87.0%) for follow-up testing. The ICA-based tests using monoclonal antibody had also high performance (sensitivity: 90%, 100%; specificity: 93.6%, 94.9%) in a post-treatment setting.²⁵

Table 3: Test Performance Results of Different Stool Antigen Test Kits Used for follow-up Testing after Treatment

Stool antigen test kit	Reference standard	Sensitivity (%)	Specificity (%)
EIA-based (monoclonal)			
Testmate rapid pylori antigen (Rapid TPAG) ²⁴	Endoscopy (histopathology)	Agreement /accuracy with urea breath test: 94.1%/96.0% Agreement /accuracy with histopathology: 94.1%/98.0%	
Amplified IDEIA Hp StAR ²⁵	Endoscopy (histopathology) or urea breath test	100	93.6
TPAg EIA ²⁷	Urea breath test	Agreement with urea breast test: 91.2%	
HpSA ELISA II ²⁷	Urea breath test	Agreement with urea breast test: 95.4%	
TPAg EIA ²⁸	Urea breath test	Agreement with urea breast test: 94.7%	
Testmate pylori antigen EIA ²⁹	Urea breath test	91.6	98.4
EIA-based (polyclonal)			
Premier Platinum HpSA ²⁶	Urea breast test	42.8	93.3
HpSA ²⁹		87.0	97.5
ICA-based (monoclonal)			
RAPID Hp StAR ²⁵	Endoscopy (histopathology) or urea breath test	100	93.6
ImmunoCard STAT! HpSA ²⁵	Endoscopy (histopathology) or urea breath test	90.0	94.9

C. Economic studies

Shultz et al. (2014)³¹ investigated whether a screening and eradication approach would be cost effective in high prevalence populations. Stool antigen testing with repeat testing after treatment was the most cost effective approach compared to urea breath testing or endoscopy. The net cost per cancer prevented per 1000 people was US\$111,800 (assuming 75% prevalence), \$132,300 (50%) and \$193,900 (25%). These values were considerable less than those of urea breath test and endoscopy for all assumed prevalences (Appendix 9). With 75% prevalence, stool antigen testing with repeat testing was expected to prevent 3.0 gastric cancers and 22.8 ulcers for every 1000 people managed. These values were similar to those of urea breath test and endoscopy. The test and retest after treatment strategy using stool antigen remained cost effective compared to others, even with a prevalence of 25%. It was concluded that the use of stool antigen testing in reducing the burden of gastric cancer and peptic ulceration in high prevalence populations is the most cost effective approach.

Holmes et al. (2010)³⁰ compared to cost-effectiveness of various non-invasive testing strategies including serology and urea breath tests. The empiric proton pump inhibitor therapy, where non-invasive testing was skipped, was used as the control. Under base case scenarios, cost-effectiveness ratios (cost per symptom free year) of the non-invasive test strategies ranged from \$123 (stool antigen) to \$129 (IgG/IgA combined serology), and were similar to that of empiric proton pump inhibitor therapy (\$122). Sensitivity analysis showed that the results were not affected by changes in prevalence of *H. pylori* (5% to 40%). Of note, this study focused on dyspepsia relief only and did not consider more serious illness such as gastric ulcer or cancer. It was concluded that “*the initial choice of noninvasive testing strategy does not have a significant influence on the overall cost-effectiveness of care for patients presenting with previously uninvestigated dyspepsia.*”

D. Guidelines

The European guideline had three recommendation statements on stool antigen tests for *H. pylori* infection (Appendix 10).

- The test was recommended for test-and-treat strategy (Grade B, Level 2a)
- The diagnostic performance of stool antigen test is equivalent to urea breath test if the validated laboratory-based monoclonal test is used (Grade A, Level 1a)
- For follow-up testing after eradication therapy, the urea breath test or a laboratory-based validated monoclonal stool test are both recommended (Grade A, Level 1a)

Limitations

The limitations of the diagnostic accuracy studies were the heterogeneity in the type of test kits used (EIA versus ICA, and monoclonal versus polyclonal), and the potential errors in sample preparations from different laboratories. In addition, the cut-off values for EIA-based tests and the reference standards varied among studies. Some reference standards might not be reliable to correctly classify the target condition.

The main limitations of the economic studies^{30,31} were the clinical assumptions including the assumed practice pattern and the probability and cost values, and the estimations of benefits of screening and treatment. The cost-effectiveness study by Holmes et al. (2010)³⁰ did not report the results in terms of quality-adjusted life years due to lack of data for patients with dyspepsia. It was unclear how the results of the included economic studies could be interpreted in a Canadian context.

The European guideline³² had no significant limitations, except an update version may be needed to better reflect the current evidence. There were no Canadian guidelines identified in the literature search.

CONCLUSIONS AND IMPLICATIONS FOR DECISION OR POLICY MAKING

In this review, 21 reports on fecal antigen detection studies (15 on diagnosis and six on follow-up testing), two economic studies and one guideline were identified. Among EIA-based tests, three test kits (Testmate pylori antigen [TPAg EIA], Premier Platinum HpSA, and Amplified IDEIA Hp Star) using monoclonal antibody and one test kit (EZ-STEP *H. pylori*) using polyclonal antibodies appeared to have highest test performance. Among the ICA-based tests, the Atlas *H. pylori* antigen monoclonal-based test had highest test performance compared to other test kits using monoclonal antibody or those using polyclonal antibodies. The EIA-based and ICA-based tests using monoclonal antibody were comparable with endoscopy (histopathology) and/or urea breath test to determine the results of *H. pylori* eradication therapy. Evidence on clinical effectiveness regarding clinical benefit, patient harms and safety was not identified. Economic studies showed that the use of stool antigen testing in relieving symptoms of dyspepsia or reducing the burden of gastric cancer and peptic ulceration in high prevalence populations was cost-effective. A laboratory-based validated monoclonal stool test is recommended for test-and-treat strategy and for follow-up testing after eradication therapy.

PREPARED BY:

Canadian Agency for Drugs and Technologies in Health

Tel: 1-866-898-8439

www.cadth.ca

REFERENCES

1. Canadian Digestive Health Foundation. In 2008, \$21 million was spent on prescription drugs for the treatment of ulcerative colitis [Internet]. Oakville (ON): The Foundation; 2014. [cited 2014 Dec 11]. Available from: [http://www.cdhf.ca/en/statistics#Ulcerative Colitis](http://www.cdhf.ca/en/statistics#Ulcerative_Colitis)
2. Logan RP, Walker MM. ABC of the upper gastrointestinal tract: Epidemiology and diagnosis of *Helicobacter pylori* infection. *BMJ* [Internet]. 2001 Oct 20 [cited 2014 Dec 11];323(7318):920-2. Available from: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1121445>
3. Lopes AI, Vale FF, Oleastro M. *Helicobacter pylori* infection - recent developments in diagnosis. *World J Gastroenterol* [Internet]. 2014 Jul 28 [cited 2015 Jan 8];20(28):9299-313. Available from: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4110561>
4. Shimoyama T. Stool antigen tests for the management of *Helicobacter pylori* infection. *World J Gastroenterol* [Internet]. 2013 Dec 7 [cited 2014 Dec 4];19(45):8188-91. Available from: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3857440>
5. Calvet X, Lario S, Ramirez-Lazaro MJ, Montserrat A, Quesada M, Reeves L, et al. Comparative accuracy of 3 monoclonal stool tests for diagnosis of *Helicobacter pylori* infection among patients with dyspepsia. *Clin Infect Dis* [Internet]. 2010 Feb 1 [cited 2014 Dec 4];50(3):323-8. Available from: <http://cid.oxfordjournals.org/content/50/3/323.full.pdf+html>
6. Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. *Ann Intern Med*. 2011 Oct 18;155(8):529-36.
7. Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the *BMJ*. The *BMJ* Economic Evaluation Working Party. *BMJ* [Internet]. 1996 Aug 3 [cited 2015 Jan 8];313(7052):275-83. Available from: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2351717>
8. Brouwers M, Kho ME, Browman GP, Cluzeau F, Feder G, Fervers B, et al. Appraisal of guidelines for research & evaluation II. AGREE II instrument [Internet]. 2013 Sep. [cited 2014 Dec 10]. Available from: http://www.agreetrust.org/wp-content/uploads/2013/10/AGREE-II-Users-Manual-and-23-item-Instrument_2009_UPDATE_2013.pdf
9. Okuda M, Osaki T, Kikuchi S, Ueda J, Lin Y, Yonezawa H, et al. Evaluation of a stool antigen test using a monoclonal antibody for native catalase for diagnosis of *Helicobacter pylori* infection in children and adults. *J Med Microbiol*. 2014 Oct 20.
10. Osman HA, Hasan H, Suppian R, Bahar N, Hussin NS, Rahim AA, et al. Evaluation of the Atlas *Helicobacter pylori* stool antigen test for diagnosis of infection in adult patients. *Asian Pac J Cancer Prev* [Internet]. 2014 [cited 2015 Jan 8];15(13):5245-7. Available from: http://www.apocpcontrol.org/paper_file/issue_abs/Volume15_No13/5245-5247%203.31%20Hussein%20Ali%20Osman.pdf


11. Alam El-Din HM, Hashem AG, Ragab YM, Hussein IL, Mohamed DB, Mohamed e. Evaluation of noninvasive versus invasive techniques for the diagnosis of *Helicobacter pylori* infection. *Appl Immunohistochem Mol Morphol*. 2013 Jul;21(4):326-33.
12. Chehter EZ, Bacci MR, Fonseca FL, Goncalves JA, Buchalla G, Shiraichi SA, et al. Diagnosis of the infection by the *Helicobacter pylori* through stool examination: method standardization in adults. *Clin Biochem*. 2013 Oct;46(15):1622-4.
13. Korkmaz H, Kesli R, Karabagli P, Terzi Y. Comparison of the diagnostic accuracy of five different stool antigen tests for the diagnosis of *Helicobacter pylori* infection. *Helicobacter*. 2013 Oct [cited 2014 Dec 4];18(5):384-91.
14. Pourakbari B, Ghazi M, Mahmoudi S, Mamishi S, Azhdarkosh H, Najafi M, et al. Diagnosis of *Helicobacter pylori* infection by invasive and noninvasive tests. *Braz J Microbiol* [Internet]. 2013 [cited 2014 Dec 4];44(3):795-8. Available from: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3910191>
15. Sharbatdaran M, Kashifard M, Shefaee S, Siadati S, Jahed B, Asgari S. Comparison of stool antigen test with gastric biopsy for the detection of *Helicobacter pylori* infection. *Pak J Med Sci* [Internet]. 2013 Jan [cited 2014 Dec 4];29(1):68-71. Available from: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3809175>
16. Tamadon MR, Saberi FM, Soleimani A, Ghorbani R, Semnani V, Malek F, et al. Evaluation of noninvasive tests for diagnosis of *Helicobacter pylori* infection in hemodialysis patients. *J Nephrothol* [Internet]. 2013 Oct [cited 2014 Dec 4];2(4):249-53. Available from: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3891128>
17. Aktepe OC, Ciftci IH, Safak B, Uslan I, Dilek FH. Five methods for detection of *Helicobacter pylori* in the Turkish population. *World J Gastroenterol* [Internet]. 2011 Dec 21 [cited 2014 Dec 4];17(47):5172-6. Available from: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3243883>
18. Ceken N, Yurtsever SG, Baran N, Alper E, Buyrac Z, Unsal B. Comparison of *Helicobacter pylori* antibody detection in stool with other diagnostic tests for infection. *Asian Pac J Cancer Prev* [Internet]. 2011 [cited 2014 Dec 4];12(4):1077-81. Available from: http://www.apocpcontrol.org/paper_file/issue_abs/Volume12_No4/1077-81%20c%203.29%20Nihan%20Ceken.pdf
19. Choi J, Kim CH, Kim D, Chung SJ, Song JH, Kang JM, et al. Prospective evaluation of a new stool antigen test for the detection of *Helicobacter pylori*, in comparison with histology, rapid urease test, (13)C-urea breath test, and serology. *J Gastroenterol Hepatol*. 2011 Jun;26(6):1053-9.
20. Kazemi S, Tavakkoli H, Habizadeh MR, Emami MH. Diagnostic values of *Helicobacter pylori* diagnostic tests: stool antigen test, urea breath test, rapid urease test, serology and histology. *J Res Med Sci* [Internet]. 2011 Sep [cited 2014 Dec 4];16(9):1097-104. Available from: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3430034>

21. Kesli R, Gokturk HS, Erbayrak M, Karabagli P, Terzi Y. Comparison of the diagnostic values of the 3 different stool antigen tests for the noninvasive diagnosis of *Helicobacter pylori* infection. *J Investig Med*. 2010 Dec;58(8):982-6.
22. Silva JM, Villares CA, Monteiro MS, Colauto C, dos Santos AF, Mattar R. Validation of a rapid stool antigen test for diagnosis of *Helicobacter pylori* infection. *Rev Inst Med Trop Sao Paulo* [Internet]. 2010 May [cited 2014 Dec 4];52(3):125-8. Available from: <http://www.scielo.br/pdf/rimtsp/v52n3/a02v52n3.pdf>
23. Calvet X, Sanchez-Delgado J, Montserrat A, Lario S, Ramirez-Lazaro MJ, Quesada M, et al. Accuracy of diagnostic tests for *Helicobacter pylori*: a reappraisal. *Clin Infect Dis* [Internet]. 2009 May 15 [cited 2014 Dec 4];48(10):1385-91. Available from: <http://cid.oxfordjournals.org/content/48/10/1385.full.pdf+html>
24. Shimoyama T, Sawaya M, Ishiguro A, Hanabata N, Yoshimura T, Fukuda S. Applicability of a rapid stool antigen test, using monoclonal antibody to catalase, for the management of *Helicobacter pylori* infection. *J Gastroenterol* [Internet]. 2011 Apr [cited 2014 Dec 4];46(4):487-91. Available from: <http://www0.nih.go.jp/JJID/62/225.pdf>
25. Calvet X, Lario S, Ramirez-Lazaro MJ, Montserrat A, Quesada M, Reeves L, et al. Accuracy of monoclonal stool tests for determining cure of *Helicobacter pylori* infection after treatment. *Helicobacter*. 2010 Jun;15(3):201-5.
26. Falaknazi K, Jalalzadeh M, Vafaeimanesh J. Noninvasive stool antigen assay for screening of *Helicobacter pylori* infection and assessing success of eradication therapy in patients on hemodialysis. *Iran J Kidney Dis* [Internet]. 2010 Oct [cited 2014 Dec 4];4(4):317-21. Available from: <http://www.ijkd.org/index.php/ijkd/article/view/270/226>
27. Shimoyama T, Kobayashi I, Kato C, Kodama M, Fukuda Y. Comparison of monoclonal antibody-based stool antigen tests to determine the results of *Helicobacter pylori* eradication therapy. *Scand J Gastroenterol*. 2010 Dec;45(12):1431-4.
28. Shimoyama T, Kato C, Kodama M, Kobayashi I, Fukuda Y. Applicability of a monoclonal antibody-based stool antigen test to evaluate the results of *Helicobacter pylori* eradication therapy. *Jpn J Infect Dis*. 2009 May;62(3):225-7.
29. Deguchi R, Matsushima M, Suzuki T, Mine T, Fukuda R, Nishina M, et al. Comparison of a monoclonal with a polyclonal antibody-based enzyme immunoassay stool test in diagnosing *Helicobacter pylori* infection after eradication therapy. *J Gastroenterol*. 2009;44(7):713-6.
30. Holmes KP, Fang JC, Jackson BR. Cost-effectiveness of six strategies for *Helicobacter pylori* diagnosis and management in uninvestigated dyspepsia assuming a high resource intensity practice pattern. *BMC Health Serv Res* [Internet]. 2010 [cited 2014 Dec 4];10:344. Available from: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3022876>
31. Schulz TR, McBryde ES, Leder K, Biggs BA. Using stool antigen to screen for *Helicobacter pylori* in immigrants and refugees from high prevalence countries is relatively cost effective in reducing the burden of gastric cancer and peptic ulceration. *PLoS ONE*

[Internet]. 2014 [cited 2014 Dec 15];9(9):e108610. Available from:
<http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4182532>

32. Malfertheiner P, Megraud F, O'Morain CA, Atherton J, Axon AT, Bazzoli F, et al. Management of *Helicobacter pylori* infection--the Maastricht IV/ Florence Consensus Report. *Gut* [Internet]. 2012 May [cited 2014 Dec 4];61(5):646-64. Available from:
<http://gut.bmj.com/content/61/5/646.full.pdf+html>

APPENDIX 1: Selection of Included Studies



APPENDIX 2: Characteristics of Included Clinical Studies

First Author, Publication Year, Country	Patient characteristics, sample Size (n)	Intervention	Comparators	Gold Standard	Outcomes
Fecal antigen detection studies (for diagnosis)					
Okuda et al. (2014) ⁹ Japan	Retrospective study: Stool samples from 99 adults and 52 children stored between -30 and 80°C.	<u>EIA-based test:</u> Monoclonal Testmate pylori antigen (TPAg EIA, Wakamoto Co.) Cut-off: 0.100	none	Stool PCR	Sensitivity, specificity, accuracy
Osman et al. (2014) ¹⁰ Malaysia	Prospective study: 59 adult dyspeptic patients	<u>ICA-based test:</u> Atlas <i>Helicobacter pylori</i> antigen test (Atlas medical, UK), a rapid immunoassay using monoclonal anti- <i>H. pylori</i> antibody	none	Endoscopy (rapid urease test)	Sensitivity, specificity, PPV, NPV, accuracy
Alam El-Din et al. (2013) ¹¹ Egypt	Prospective study: 52 patients (age: NR) suffering from gastrointestinal disorders. Pathological data were available from 19 patients only	<u>EIA-based using polyclonal antibodies</u> (Immunodiagnostik AG, Gernamy) Cut-off: NR	Endoscopy (histopathology using Hematoxylin and Eosin stain)	Endoscopy (histopathology using giemsa stain)	Sensitivity, specificity, PPV, NPV
Chehter et al. (2013) ¹² Brazil	Cross-sectional study: test results of 75 patients had clinical indication for high digestive endoscopy	<u>EIA-based test:</u> Monoclonal Amplified IDEIA Hp Star (DAKO Cytomation, Denmark) Cut-off: NR	Endoscopy (rapid urease test)	Two positive tests: gastric biopsy plus one of urease, breath or serology	Sensitivity, specificity
Korkmaz et al. (2013) ¹³ Turkey	Prospective study: 198 adult patients (75 men, 123 women; mean age (SD): 49.3 (15.0) years) with dyspeptic symptoms	<u>EIA-based tests:</u> Two monoclonal stool EIA tests (Premier Platinum HpSA Plus and HP Ag) Cut-off: 0.100 or greater	Three rapid ICA tests: •Two monoclonal ICA tests (ImmunoCard STAT! HpSA and <i>H. pylori</i> fecal antigen) •One polyclonal ICA	Two invasive tests (histological and rapid urease tests) were positive	Sensitivity, specificity

First Author, Publication Year, Country	Patient characteristics, sample Size (n)	Intervention	Comparators	Gold Standard	Outcomes
			stool antigen test (one-step <i>H. pylori</i> antigen test)		
Pourakbari et al. (2013) ¹⁴ Iran	Prospective study: 89 patients (61 adults, 28 children) referred to hospital for diagnostic upper gastrointestinal endoscopy Mean age (SD): 44.7 (18.7) years for adults and 9.9 (2.6) years for children	<u>EIA-based test:</u> Monoclonal Stool antigen EIA test (ASTRA, Italy) Cut-off: NR	Endoscopy (rapid urease test, histopathology)	Positive results: confirmed by PCR on biopsy samples Negative results: confirmed by all invasive tests	Sensitivity, specificity, PPV, NPV, accuracy
Sharbatdaran et al. (2013) ¹⁵ Iran	Prospective study: 61 patients under 45 years of age with dyspeptic symptoms underwent upper endoscopy and gastric biopsy	<u>EIA-based test:</u> Monoclonal <i>H. pylori</i> stool antigen (HpSA) test (GA Generic Assay, Germany) Cut-off: NR	none	Endoscopy (histopathology using hematoxylin and eosin and modified giemsa)	Sensitivity, specificity, PPV, NPV
Tamadon et al. (2013) ¹⁶ Iran	Prospective study: 50 hemodialysis patients (30 men, 20 women); mean age (SD): 70 (15.8) years; hemodialysis duration (SD): 32.3 (28.3) months	<u>EIA-based test:</u> Monoclonal <i>H. pylori</i> stool antigen (HpSA) test (IBL kit, Germany) Cut-off: 0.100	Urea breath test	At least two out of three tests (urea breath test, stool antigen test and serology) were positive	Sensitivity, specificity, PPV, NPV
Aktepe et al. (2011) ¹⁷ Turkey	Prospective study: 132 adult dyspeptic patients receiving diagnostic endoscopy	<u>EIA-based test:</u> Monoclonal antigen FemtoLab <i>H. pylori</i> Cnx kits (Connex GmbH, Martinsried, Germany) Cut-off: NR	Endoscopy (culture, biopsy PCR, FISH)	Endoscopy (histopathology using giemsa and hematoxylin and eosin)	Sensitivity, specificity, PPV, NPV
Ceken et al. (2011) ¹⁸	Prospective study: 100 dyspeptic patients	<u>ICA-based test:</u> Monoclonal Helicobacter	Endoscopy (rapid urease test)	Endoscopy (histopathology)	Sensitivity, specificity, PPV, NPV,

First Author, Publication Year, Country	Patient characteristics, sample Size (n)	Intervention	Comparators	Gold Standard	Outcomes
Turkey	(mean age [SD]: 47.6 [17] years) receiving diagnostic endoscopy	antigen Quick Castle test kit (GENERIC ASSAYS GmbH, Germany)			accuracy
Choi et al. (2011) ¹⁹ South Korea	Prospective study: 515 consecutive patients (288 women, mean age: 47.8 ± 9.6 years) undergoing routine health check-ups.	<u>EIA-based test using polyclonal antibodies</u> EZ-STEP <i>H. pylori</i> Cut-off: 0.160	Endoscopy (rapid urease test) Urea breath test	At least two of four tests (histology, rapid urease test, urea breath test, and serology) were positive	Sensitivity, specificity, PPV, NPV, accuracy
Kazemi et al. (2011) ²⁰ Iran	Prospective study: 110 dyspeptic patients (55 women, age range: 20 to 72 years) who had indication of upper gastrointestinal endoscopy. 16 patients were excluded and 94 patients were available for analysis	<u>ICA-based test:</u> Monoclonal GENERIC ASSAYS GmbH, Germany)	Endoscopy (rapid urease test) Urea breath test	At least two of five tests (stool antigen test, urea breath test, rapid urease test, serology and histology) were positive	Sensitivity, specificity, PPV, NPV, accuracy
Kesli et al. (2010) ²¹ Turkey	Prospective study: 168 adult dyspeptic patients (52 women, mean age: 46.1 ± 14.2 years) went to hospital for routine upper gastrointestinal endoscopy	<u>EIA-based tests:</u> Monoclonal Premier Platinum HpSA Plus (Meridian Bioscience, Inc, cincinnati, OH) Hp Ag (Dia.Pro Diagnostic Bioprobes Srl, Milano, Italy) Cut-off: 0.100	<u>ICA-based test:</u> Polyclonal <i>H. pylori</i> fecal antigen test (Vegal Farmaceutical, Madrid, Spain)	Endoscopy (histopathology and rapid urease test)	Sensitivity, specificity, PPV, NPV, accuracy
Silva et al. (2010) ²² Brazil	Prospective study: 98 consecutive patients, asymptomatic or dyspeptic (69 women, mean	<u>ICA-based test:</u> Monoclonal One step <i>H. pylori</i> antigen test device, IHP-602, ACON laboratories, Inc,	none	¹³ C-urea breath test	Sensitivity, specificity, PPV, NPV

First Author, Publication Year, Country	Patient characteristics, sample Size (n)	Intervention	Comparators	Gold Standard	Outcomes
	age: 45.8 ± 14.6 years)	San Diego, USA; Prime diagnostics, Sao Paulo, Brazil			
Calvet et al. (2009) ²³ Spain	Prospective study: 199 dyspeptic patients (107 women, mean age: 48.2 ± 14.2 years), had endoscopic examination	<u>EIA-based test:</u> Monoclonal EIA (Amplified IDEIA Hp StAR [Thermo Fisher Scientific]) Cut-off: 0.150	Endoscopy (histology, rapid urease test) Urea breath test	At least two of four tests (histopathology, rapid urease test, urea breath test, and fecal test) were positive	Sensitivity, specificity, PPV, NPV
Fecal antigen detection studies (for follow-up testing)					
Shimoyama et al. (2011) ²⁴ Japan	Prospective study: 102 consecutive patients (48 women, mean age: 60.0 years) received H. pylori eradication therapy	<u>EIA-based test:</u> Monoclonal EIA Testmate rapid pylori antigen (Rapid TPAg; Wakamoto Pharmaceutical Co., Ltd, Kanagawa, Japan) Cut-off: NR	Urea breath test	Endoscopy (histopathology)	Agreement, accuracy
Calvet et al. (2010) ²⁵ Spain	Prospective study: 88 patients (26 women, mean age: 58.3 ± 17.7 years) had at least 8 weeks H. pylori treatment	<u>EIA-based test:</u> Monoclonal Amplified IDEIA Hp StAR Cut-off: 0.150	<u>ICA-based tests</u> (monoclonal): • RAPID Hp StAR • ImmunoCard STAT! HpSA	Endoscopy (histopathology) or urea breath test	Sensitivity, specificity, PPV, NPV
Falaknazi et al. (2010) ²⁶ Iran	Cross-sectional study: 87 hemodialysis patients (21 women, mean age: 59 years) who had H. pylori infection and had at least 8 weeks H. pylori treatment	<u>EIA-based test using polyclonal antibodies:</u> Premier Platinum HpSA (Astra SRL, Via Ciro Menotti, Milano, Italy) Cut-off: 0.12	none	Gold for diagnosis At least two of three tests (serology, urea breath test, and fecal test) were positive <u>Gold for follow-up testing</u> Urea breath test	Sensitivity, specificity, PPV, NPV
Shimoyama et al. (2010) ²⁷ Japan	Prospective study: 239 adult patients (115 women, mean age: 53.8 years)	<u>EIA-based tests:</u> Monoclonal • TPAg EIA • HpSA ELISA II	none	Urea breath test	Agreement between two tests Agreement to urea

First Author, Publication Year, Country	Patient characteristics, sample Size (n)	Intervention	Comparators	Gold Standard	Outcomes
	received H. pylori eradication therapy for 5 to 8 weeks.	Cut-off: NR			breath test
Shimoyama et al. (2009) ²⁸ Japan	Prospective study: 94 patients received H. pylori eradication therapy for 6 to 8 weeks.	<u>EIA-based test:</u> TPAg EIA (monoclonal) Cut-off: NR	none	Urea breath test	Agreement to urea breath test
Degichi et al. (2009) ²⁹ Japan	Prospective study: 150 patients received H. pylori eradication therapy for 4 to 8 weeks.	<u>EIA-based test:</u> Testmate H. pylori antigen EIA (monoclonal) Cut-off: 0.100	<u>EIA-based test:</u> HpSA (polyclonal) Cut-off: <0.100 negative, >0.120 positive, 0.100 to 0.119 equivocal	Urea breath test	Sensitivity, specificity
EIA = enzyme immunoassay; FISH = fluorescence <i>in situ</i> hybridization; ICA = immunochromatographic assay; NPV = negative predictive value; NR = not reported; PCR = polymerase chain reaction; PPV = positive predictive value; SD = standard deviation					

APPENDIX 3: Characteristics of Economic Studies

First Author, Publication Year, Country	Study design	Perspective, Time Horizon, Dollar, Discounting	Population, Inclusion criteria	Intervention, comparator	Cost included
Schulz et al. (2014) ³¹ Australia	CMA – decision analytic model 1° outcome: net cost per cancer prevented per 1000 people Sensitivity analysis on stool testing with retesting of those treated	Payer Lifetime US\$ No discounting	Immigrants and refugees from high prevalence developing countries	<u>Interventions:</u> Nine different screening and follow-up strategies <u>Comparators:</u> Treat all without screening	Costs of testing, and costs of adverse events associated with <i>H. pylori</i> Other costs: cost of managing one cancer, cost of a physician visit, cost of medication for eradication, cost of managing one peptic ulcer and lifetime risk of gastric cancer
Holmes et al. (2010) ³⁰ USA	Cost-effectiveness 1° outcome: Cost (US\$) per symptom-free year Markov model Probabilistic sensitivity analysis (changes in <i>H. pylori</i> prevalence)	Societal Lifetime US\$ No discounting	Dyspeptic patients with probability having <i>H. pylori</i> infection, peptic ulcer(s), or both Only patients younger than 55 years	IgG/IgA IgG Stool antigen IgG with reflex to Stool antigen Urea breath test PPI therapy [Begin with each of the first five tests; if positive, do triple therapy; if negative, do PPI therapy] [if there is no relief of symptoms after initial management, or if symptoms recur, patients will go on to receive an endoscopy with biopsy]	Baseline costs of tests and treatments were based on 2009 national midpoint Medicare reimbursement rates.
CMA = cost minimization analysis; IgA = immunoglobulin; IgG = immunoglobulin G; PPI = proton pump inhibitor					

APPENDIX 4: Grading of Recommendations and Levels of Evidence

Guideline Society or Institute	Recommendation		Level of Evidence	
European Helicobacter Study Group (2012) ³²	Grade of recommendation	Evidence level	Type of study	
	A	1	1a	Systematic review of RCT of good methodological quality and with homogeneity
			1b	Individual RCT with narrow CI
			1c	Individual RCT with risk of bias
	B	2	2a	Systematic review of cohort studies (with homogeneity)
			2b	Individual cohort study (including low quality RCT, e.g. <80% follow-up)
			2c	Non-controlled cohort studies/ecological studies
		3	3a Systematic review of case control-studies (with homogeneity)	
C	4	3b	Individual case-control study	
D	5		Case series/poor quality cohort or case-control studies	
			Expert opinion without critical appraisal or based on physiology, bench research or 'first principles'	

CI = confidence interval; RCT = randomized controlled trial

APPENDIX 5: Summary of Study Strengths and Limitations – Diagnostic studies

First Author, Publication Year, Country	Strengths and Limitations
<i>Fecal antigen detection studies (for diagnosis)</i>	
Okuda et al. (2014) ⁹ Japan	<p><u>Domain 1: Patient selection</u></p> <ul style="list-style-type: none"> • Risk of bias: low • Concerns regarding applicability: low <p><u>Domain 2: Index test(s)</u></p> <ul style="list-style-type: none"> • Risk of bias: low • Concerns regarding applicability: low <p><u>Domain 3: Reference standard</u></p> <ul style="list-style-type: none"> • Risk of Bias: unclear [if correctly classify the target condition] • Concerns regarding applicability: low <p><u>Domain 4: Flow and timing</u></p> <ul style="list-style-type: none"> • Risk of bias: high [not all patients received a reference standard]
Osman et al. (2014) ¹⁰ Malaysia	<p><u>Domain 1: Patient selection</u></p> <ul style="list-style-type: none"> • Risk of bias: low • Concerns regarding applicability: low <p><u>Domain 2: Index test(s)</u></p> <ul style="list-style-type: none"> • Risk of bias: low • Concerns regarding applicability: low <p><u>Domain 3: Reference standard</u></p> <ul style="list-style-type: none"> • Risk of Bias: unclear [if correctly classify the target condition] • Concerns regarding applicability: low <p><u>Domain 4: Flow and timing</u></p> <ul style="list-style-type: none"> • Risk of bias: low
Alam El-Din et al. (2013) ¹¹ Egypt	<p><u>Domain 1: Patient selection</u></p> <ul style="list-style-type: none"> • Risk of bias: high [63% patients were excluded from the study] • Concerns regarding applicability: high [63% patients were excluded from the study] <p><u>Domain 2: Index test(s)</u></p> <ul style="list-style-type: none"> • Risk of bias: low • Concerns regarding applicability: low <p><u>Domain 3: Reference standard</u></p> <ul style="list-style-type: none"> • Risk of Bias: low • Concerns regarding applicability: low <p><u>Domain 4: Flow and timing</u></p> <ul style="list-style-type: none"> • Risk of bias: high [63% patients did not have pathologic data]
Chehter et al. (2013) ¹² Brazil	<p><u>Domain 1: Patient selection</u></p> <ul style="list-style-type: none"> • Risk of bias: unclear [if the study avoided inappropriate exclusions] • Concerns regarding applicability: low <p><u>Domain 2: Index test(s)</u></p> <ul style="list-style-type: none"> • Risk of bias: low • Concerns regarding applicability: low

First Author, Publication Year, Country	Strengths and Limitations
	<p><u>Domain 3: Reference standard</u></p> <ul style="list-style-type: none"> • Risk of Bias: low • Concerns regarding applicability: low <p><u>Domain 4: Flow and timing</u></p> <ul style="list-style-type: none"> • Risk of bias: high [not all patients received index test and/or reference standard]
<p>Korkmaz et al. (2013)¹³</p> <p>Turkey</p>	<p><u>Domain 1: Patient selection</u></p> <ul style="list-style-type: none"> • Risk of bias: low • Concerns regarding applicability: low <p><u>Domain 2: Index test(s)</u></p> <ul style="list-style-type: none"> • Risk of bias: low • Concerns regarding applicability: low <p><u>Domain 3: Reference standard</u></p> <ul style="list-style-type: none"> • Risk of Bias: low • Concerns regarding applicability: low <p><u>Domain 4: Flow and timing</u></p> <ul style="list-style-type: none"> • Risk of bias: low
<p>Pourakbari et al. (2013)¹⁴</p> <p>Iran</p>	<p><u>Domain 1: Patient selection</u></p> <ul style="list-style-type: none"> • Risk of bias: low • Concerns regarding applicability: low <p><u>Domain 2: Index test(s)</u></p> <ul style="list-style-type: none"> • Risk of bias: low • Concerns regarding applicability: low <p><u>Domain 3: Reference standard</u></p> <ul style="list-style-type: none"> • Risk of Bias: low • Concerns regarding applicability: low <p><u>Domain 4: Flow and timing</u></p> <ul style="list-style-type: none"> • Risk of bias: low
<p>Sharbatdaran et al. (2013)¹⁵</p> <p>Iran</p>	<p><u>Domain 1: Patient selection</u></p> <ul style="list-style-type: none"> • Risk of bias: low • Concerns regarding applicability: low <p><u>Domain 2: Index test(s)</u></p> <ul style="list-style-type: none"> • Risk of bias: low • Concerns regarding applicability: low <p><u>Domain 3: Reference standard</u></p> <ul style="list-style-type: none"> • Risk of Bias: low • Concerns regarding applicability: low <p><u>Domain 4: Flow and timing</u></p> <ul style="list-style-type: none"> • Risk of bias: low
<p>Tamadon et al. (2013)¹⁶</p> <p>Iran</p>	<p><u>Domain 1: Patient selection</u></p> <ul style="list-style-type: none"> • Risk of bias: low • Concerns regarding applicability: low <p><u>Domain 2: Index test(s)</u></p> <ul style="list-style-type: none"> • Risk of bias: low

First Author, Publication Year, Country	Strengths and Limitations
	<ul style="list-style-type: none"> • Concerns regarding applicability: low <p><u>Domain 3: Reference standard</u></p> <ul style="list-style-type: none"> • Risk of Bias: unclear [if correctly classify the target condition] • Concerns regarding applicability: low <p><u>Domain 4: Flow and timing</u></p> <ul style="list-style-type: none"> • Risk of bias: low
<p>Aktepe et al. (2011)¹⁷</p> <p>Turkey</p>	<p><u>Domain 1: Patient selection</u></p> <ul style="list-style-type: none"> • Risk of bias: low • Concerns regarding applicability: low <p><u>Domain 2: Index test(s)</u></p> <ul style="list-style-type: none"> • Risk of bias: low • Concerns regarding applicability: low <p><u>Domain 3: Reference standard</u></p> <ul style="list-style-type: none"> • Risk of Bias: low • Concerns regarding applicability: low <p><u>Domain 4: Flow and timing</u></p> <ul style="list-style-type: none"> • Risk of bias: low
<p>Ceken et al. (2011)¹⁸</p> <p>Turkey</p>	<p><u>Domain 1: Patient selection</u></p> <ul style="list-style-type: none"> • Risk of bias: low • Concerns regarding applicability: low <p><u>Domain 2: Index test(s)</u></p> <ul style="list-style-type: none"> • Risk of bias: low • Concerns regarding applicability: low <p><u>Domain 3: Reference standard</u></p> <ul style="list-style-type: none"> • Risk of Bias: low • Concerns regarding applicability: low <p><u>Domain 4: Flow and timing</u></p> <ul style="list-style-type: none"> • Risk of bias: low
<p>Choi et al. (2011)¹⁹</p> <p>South Korea</p>	<p><u>Domain 1: Patient selection</u></p> <ul style="list-style-type: none"> • Risk of bias: low • Concerns regarding applicability: low <p><u>Domain 2: Index test(s)</u></p> <ul style="list-style-type: none"> • Risk of bias: low • Concerns regarding applicability: low <p><u>Domain 3: Reference standard</u></p> <ul style="list-style-type: none"> • Risk of Bias: low • Concerns regarding applicability: low <p><u>Domain 4: Flow and timing</u></p> <ul style="list-style-type: none"> • Risk of bias: low
<p>Kazemi et al. (2011)²⁰</p> <p>Iran</p>	<p><u>Domain 1: Patient selection</u></p> <ul style="list-style-type: none"> • Risk of bias: unclear [16% patients were excluded] • Concerns regarding applicability: low <p><u>Domain 2: Index test(s)</u></p> <ul style="list-style-type: none"> • Risk of bias: low

First Author, Publication Year, Country	Strengths and Limitations
	<ul style="list-style-type: none"> • Concerns regarding applicability: low <p><u>Domain 3: Reference standard</u></p> <ul style="list-style-type: none"> • Risk of Bias: low • Concerns regarding applicability: low <p><u>Domain 4: Flow and timing</u></p> <ul style="list-style-type: none"> • Risk of bias: low
Kesli et al. (2010) ²¹ Turkey	<p><u>Domain 1: Patient selection</u></p> <ul style="list-style-type: none"> • Risk of bias: low • Concerns regarding applicability: low <p><u>Domain 2: Index test(s)</u></p> <ul style="list-style-type: none"> • Risk of bias: low • Concerns regarding applicability: low <p><u>Domain 3: Reference standard</u></p> <ul style="list-style-type: none"> • Risk of Bias: low • Concerns regarding applicability: low <p><u>Domain 4: Flow and timing</u></p> <ul style="list-style-type: none"> • Risk of bias: low
Silva et al. (2010) ²² Brazil	<p><u>Domain 1: Patient selection</u></p> <ul style="list-style-type: none"> • Risk of bias: low • Concerns regarding applicability: low <p><u>Domain 2: Index test(s)</u></p> <ul style="list-style-type: none"> • Risk of bias: low • Concerns regarding applicability: low <p><u>Domain 3: Reference standard</u></p> <ul style="list-style-type: none"> • Risk of Bias: unclear [if correctly classify the target condition] • Concerns regarding applicability: low <p><u>Domain 4: Flow and timing</u></p> <ul style="list-style-type: none"> • Risk of bias: low
Calvet et al. (2009) ²³ Spain	<p><u>Domain 1: Patient selection</u></p> <ul style="list-style-type: none"> • Risk of bias: low • Concerns regarding applicability: low <p><u>Domain 2: Index test(s)</u></p> <ul style="list-style-type: none"> • Risk of bias: low • Concerns regarding applicability: low <p><u>Domain 3: Reference standard</u></p> <ul style="list-style-type: none"> • Risk of Bias: low • Concerns regarding applicability: low <p><u>Domain 4: Flow and timing</u></p> <ul style="list-style-type: none"> • Risk of bias: low
Fecal antigen detection studies (for follow-up testing)	
Shimoyama et al. (2011) ²⁴ Japan	<p><u>Domain 1: Patient selection</u></p> <ul style="list-style-type: none"> • Risk of bias: low • Concerns regarding applicability: low

First Author, Publication Year, Country	Strengths and Limitations
	<p><u>Domain 2: Index test(s)</u></p> <ul style="list-style-type: none"> • Risk of bias: low • Concerns regarding applicability: low <p><u>Domain 3: Reference standard</u></p> <ul style="list-style-type: none"> • Risk of Bias: unclear [if correctly classify the target condition] • Concerns regarding applicability: low <p><u>Domain 4: Flow and timing</u></p> <ul style="list-style-type: none"> • Risk of bias: unclear [not all patients received reference standard]
<p>Calvet et al. (2010)²⁵ Spain</p>	<p><u>Domain 1: Patient selection</u></p> <ul style="list-style-type: none"> • Risk of bias: low • Concerns regarding applicability: low <p><u>Domain 2: Index test(s)</u></p> <ul style="list-style-type: none"> • Risk of bias: low • Concerns regarding applicability: low <p><u>Domain 3: Reference standard</u></p> <ul style="list-style-type: none"> • Risk of Bias: unclear [if correctly classify the target condition] • Concerns regarding applicability: low <p><u>Domain 4: Flow and timing</u></p> <ul style="list-style-type: none"> • Risk of bias: high [not all patients received reference standard]
<p>Falaknazi et al. (2010)²⁶ Iran</p>	<p><u>Domain 1: Patient selection</u></p> <ul style="list-style-type: none"> • Risk of bias: low • Concerns regarding applicability: low <p><u>Domain 2: Index test(s)</u></p> <ul style="list-style-type: none"> • Risk of bias: low • Concerns regarding applicability: low <p><u>Domain 3: Reference standard</u></p> <ul style="list-style-type: none"> • Risk of Bias: unclear [if correctly classify the target condition] • Concerns regarding applicability: low <p><u>Domain 4: Flow and timing</u></p> <ul style="list-style-type: none"> • Risk of bias: low
<p>Shimoyama et al. (2010)²⁷ Japan</p>	<p><u>Domain 1: Patient selection</u></p> <ul style="list-style-type: none"> • Risk of bias: low • Concerns regarding applicability: low <p><u>Domain 2: Index test(s)</u></p> <ul style="list-style-type: none"> • Risk of bias: low • Concerns regarding applicability: low <p><u>Domain 3: Reference standard</u></p> <ul style="list-style-type: none"> • Risk of Bias: unclear [if correctly classify the target condition] • Concerns regarding applicability: low <p><u>Domain 4: Flow and timing</u></p> <ul style="list-style-type: none"> • Risk of bias: low
<p>Shimoyama et al. (2009)²⁸</p>	<p><u>Domain 1: Patient selection</u></p> <ul style="list-style-type: none"> • Risk of bias: low • Concerns regarding applicability: low

First Author, Publication Year, Country	Strengths and Limitations
Japan	<p><u>Domain 2: Index test(s)</u></p> <ul style="list-style-type: none"> • Risk of bias: low • Concerns regarding applicability: low <p><u>Domain 3: Reference standard</u></p> <ul style="list-style-type: none"> • Risk of Bias: unclear [if correctly classify the target condition] • Concerns regarding applicability: low <p><u>Domain 4: Flow and timing</u></p> <ul style="list-style-type: none"> • Risk of bias: low
Degichi et al. (2009) ²⁹ Japan	<p><u>Domain 1: Patient selection</u></p> <ul style="list-style-type: none"> • Risk of bias: low • Concerns regarding applicability: low <p><u>Domain 2: Index test(s)</u></p> <ul style="list-style-type: none"> • Risk of bias: low • Concerns regarding applicability: low <p><u>Domain 3: Reference standard</u></p> <ul style="list-style-type: none"> • Risk of Bias: unclear [if correctly classify the target condition] • Concerns regarding applicability: low <p><u>Domain 4: Flow and timing</u></p> <ul style="list-style-type: none"> • Risk of bias: low

APPENDIX 6: Summary of Study Strengths and Limitations – Economic studies

First Author, Publication Year	Strengths	Limitations
Schulz et al. (2014) ³¹	<p><u>Study design</u></p> <ul style="list-style-type: none"> • The research question is stated • The economic importance of the research question is stated • The rationale for choosing alternative programmes or interventions compared is stated • The form of economic evaluation used is stated • The choice of form of economic evaluation used is stated <p><u>Data collection</u></p> <ul style="list-style-type: none"> • The source(s) of effectiveness estimates used are stated • The primary outcome measure(s) for the economic evaluation are clearly stated • Methods to value benefit are stated • Quantities of resource use are not reported separately from their unit costs • Methods for the estimation of quantities and unit costs are described • Currency and price data are recorded • Details of currency of price adjustments for inflation or currency conversion are given • Details of any model use are given • The choice of model used and the key parameters on which it is based are justified <p><u>Analysis and interpretation of results</u></p> <ul style="list-style-type: none"> • Time horizon of costs and benefits is stated • The approach to sensitivity analysis is given • The choice of variables for sensitivity analysis is justified • Incremental analysis is reported • Major outcomes are reported in a disaggregated as well as aggregated form • The answer of the study is given • Conclusions follow from data reported 	<p><u>Analysis and interpretation of results</u></p> <ul style="list-style-type: none"> • The discount rate is not stated • Details of statistical tests are not given

First Author, Publication Year	Strengths	Limitations
Holmes et al. (2010) ³⁰	<p><u>Study design</u></p> <ul style="list-style-type: none"> • The research question is stated • The economic importance of the research question is stated • The rationale for choosing alternative programmes or interventions compared is stated • The form of economic evaluation used is stated • The choice of form of economic evaluation used is stated <p><u>Data collection</u></p> <ul style="list-style-type: none"> • The source(s) of effectiveness estimates used are stated • The primary outcome measure(s) for the economic evaluation are clearly stated • Methods for the estimation of quantities and unit costs are described • Currency and price data are recorded • Details of any model use are given <p><u>Analysis and interpretation of results</u></p> <ul style="list-style-type: none"> • Time horizon of costs and benefits is stated • The approach to sensitivity analysis is given • Incremental analysis is reported • Major outcomes are reported in a disaggregated as well as aggregated form • The answer of the study is given • Conclusions follow from data reported 	<p><u>Data collection</u></p> <ul style="list-style-type: none"> • Methods to value benefit are not stated • Quantities of resource use are not reported separately from their unit costs • Details of currency of price adjustments for inflation or currency conversion are not given • The choice of model used and the key parameters on which it is based are not justified <p><u>Analysis and interpretation of results</u></p> <ul style="list-style-type: none"> • The discount rate is not stated • The choice of variables for sensitivity analysis is not justified • Details of statistical tests are not given

APPENDIX 7: Summary of Study Strengths and Limitations – Guidelines

First Author, Publication Year	Strengths	Limitations
<p>European Helicobacter Study Group (2012)³²</p>	<p><u>Scope and purpose</u></p> <ul style="list-style-type: none"> • Objectives and target patients population were explicit • The health question covered by the guidelines is specifically described • The population to whom the guidelines is meant to apply is specifically described <p><u>Stakeholder involvement</u></p> <ul style="list-style-type: none"> • The guideline development group includes individuals from all relevant professional groups • The views and preferences of the target population have been sought • The target users of the guideline are clearly defined <p><u>Rigour of development</u></p> <ul style="list-style-type: none"> • Systematic methods were used to search for evidence • The criteria for selecting the evidence are clearly described • The strengths and limitations of the body of evidence are clearly described • The methods of formulating the recommendations are clearly described • The health benefits, side effects, and risks have been considered in formulating the recommendations • There is an explicit link between the recommendations and the supporting evidence • The guideline has been externally reviewed by experts prior to its publication <p><u>Applicability</u></p> <ul style="list-style-type: none"> • The guideline presents monitoring and/or auditing criteria <p><u>Clarity of recommendation</u></p> <ul style="list-style-type: none"> • The recommendations are specific and unambiguous • The different options for management of the condition or health issue are clearly presented • Key recommendations are easily identified <p><u>Editorial independence</u></p> <ul style="list-style-type: none"> • Competing interests of guideline development group members have been recorded and addressed 	<p><u>Rigour of development</u></p> <ul style="list-style-type: none"> • A procedure for updating the guideline is not provided <p><u>Applicability</u></p> <ul style="list-style-type: none"> • The guideline does not describe facilitators and barriers to its application • The guidelines does not provide advice and/or tools on how the recommendations can be put into practice • The potential resource implications of applying the recommendations have not been considered <p><u>Editorial independence</u></p> <ul style="list-style-type: none"> • It is unclear if the views of the funding body have influenced the content of the guideline

APPENDIX 8: Main Study Findings and Authors' Conclusions – Clinical

Study	Stool antigen test	Cut-off value	Comparators	Reference standard	Test performance	
					Stool antigen test	Comparators
Diagnostic accuracy studies (for diagnosis)						
Okuda et al. (2014) ⁹ Japan	<u>EIA-based test:</u> Monoclonal Testmate pylori antigen (TPAg EIA, Wakamoto Co.)	0.100	none	Stool PCR	Adults: Sensitivity: 92.4% Specificity: 100% Accuracy: 94.9% Children: Sensitivity: 82.7% Specificity: 100% Accuracy: 90.4%	none
Authors' conclusions: "A stool antigen test (TPAg) using mAb for native catalase is useful for diagnosis of <i>H. pylori</i> in children and adults. Additionally, this test has particularly high specificity."						
Osman et al. (2014) ¹⁰ Malaysia	<u>ICA-based test:</u> Atlas <i>Helicobacter pylori</i> antigen test (Atlas medical, UK), a rapid immunoassay using monoclonal anti- <i>H. pylori</i> antibody	NR	none	Endoscopy (rapid urease test)	Sensitivity: 91.7% Specificity: 100% PPV: 100% NPV: 94.6% Accuracy: 96.6%	none
Authors' conclusions: "The Atlas <i>H. pylori</i> antigen test is a new non-invasive method which is simple to perform and avails reliable results in a few minutes."						
Alam El-Din et al. (2013) ¹¹ Egypt	<u>EIA-based using polyclonal antibodies</u> (Immunodiagnostik AG, Germany)	Cut-off: NR	Endoscopy (histopathology using Hematoxylin and Eosin stain)	Endoscopy (histopathology using Giemsa stain)	Sensitivity: 72.2% Specificity: -- PPV: 92.9 NPV: -- (specificity and NPV could not be calculated – no true-negative cases)	<u>Histopathology</u> Sensitivity: 88.9% Specificity: 100% PPV: 100% NPV: 33.3%
Authors' conclusions: "Among the non-invasive methods for diagnosis of <i>H. pylori</i> infection, the 3 methods used in this study recorded promising results, including good sensitivity"						

Study	Stool antigen test	Cut-off value	Comparators	Reference standard	Test performance	
					Stool antigen test	Comparators
Chehter et al. (2013) ¹² Brazil	<u>EIA-based test:</u> Monoclonal Amplified IDEIA Hp Star (DAKO Cytomation, Denmark)	Cut-off: NR	Endoscopy (rapid urease test)	Two positive tests: gastric biopsy plus one of urease, breath or serology	Sensitivity: 87.2% Specificity: 44%	<u>Rapid urease test</u> Sensitivity: 65.6% Specificity: 58.8%
Authors' conclusions: "The ROC curve showed a good correlation between the compared methods. In Brazil the standardization of the ELISA test for the detection of <i>H. pylori</i> in stool specimens constitutes a non-invasive diagnostic alternative."						
Korkmaz et al. (2013) ¹³ Turkey	<u>EIA-based tests:</u> Two monoclonal stool EIA tests (Premier Platinum HpSA Plus and HP Ag)	Cut-off: 0.100 or greater for Premier Platinum HpSA Plus and HP Ag	Three rapid ICA tests: • Two monoclonal ICA tests (ImmunoCard STAT! HpSA and <i>H. pylori</i> fecal antigen) • One polyclonal ICA stool antigen test (one-step <i>H. pylori</i> antigen test)	Two invasive tests (histological and rapid urease tests) were positive	<u>Premier Platinum HpSA Plus test</u> Sensitivity: 92.2% Specificity: 94.4% <u>HP Ag test</u> Sensitivity: 48.9% Specificity: 88.9%	<u>ImmunoCard STAT! HpSA test</u> Sensitivity: 68.9% Specificity: 92.6% <u><i>H. pylori</i> fecal antigen test</u> Sensitivity: 78.9% Specificity: 87% <u>One-step <i>H. pylori</i> antigen test</u> Sensitivity: 86.7% Specificity: 88.9%
Authors' conclusions: "The Premier Platinum HpSA Plus EIA test was determined to be the most accurate stool test for diagnosis <i>H. pylori</i> infections in adult dyspeptic patients. The currently available ICA-based tests are fast and easy to use but provide less reliable results."						
Pourakbari et al. (2013) ¹⁴ Iran	<u>EIA-based test:</u> Monoclonal Stool antigen EIA test (ASTRA, Italy)	Cut-off: NR	Endoscopy (rapid urease test, histopathology)	Positive results: confirmed by PCR on biopsy samples Negative results: confirmed by all invasive tests	Sensitivity: 87.8% Specificity: 75% PPV: 81.1% NPV: 83.3% Accuracy: 82%	<u>Rapid urease test:</u> Sensitivity: 95.9% Specificity: 85% PPV: 88.7% NPV: 94.4% Accuracy: 91% <u>Histopathology:</u> Sensitivity: 100% Specificity: 90% PPV: 92.5%

Study	Stool antigen test	Cut-off value	Comparators	Reference standard	Test performance	
					Stool antigen test	Comparators
						NPV: 100% Accuracy: 95%
Authors' conclusions: "Stool antigen test can consider as a suitable non-invasive test for detection of <i>H. pylori</i> infection."						
Sharbatdaran et al. (2013) ¹⁵ Iran	<u>EIA-based test:</u> Monoclonal <i>H. pylori</i> stool antigen (HpSA) test (GA Generic Assay, Germany)	Cut-off: NR	none	Endoscopy (histopathology using hematoxylin and eosin and modified Giemsa)	Sensitivity: 66% Specificity: 91% PPV: 93% NPV: 62%	none
Authors' conclusions: "The HpSA test for the detection of <i>H. pylori</i> infection seems to be a good alternative for invasive diagnostic tests such as urea breath test, especially in our country"						
Tamadon et al. (2013) ¹⁶ Iran	<u>EIA-based test:</u> Monoclonal <i>H. pylori</i> stool antigen (HpSA) test (IBL kit, Germany)	Cut-off: 0.100	Urea breath test	At least two out of three tests (urea breath test, stool antigen test and serology) were positive	Sensitivity: 100% Specificity: 75% PPV: 60.9% NPV: 100%	Urea breath test Sensitivity: 62.5% Specificity: 65.4% PPV: 62.5% NPV: 65.4%
Authors' conclusions: "...stool antigen test has higher diagnostic values than UBT, and... more reliable than UBT in diagnosis of <i>H. pylori</i> infection in hemodialysis patients"						
Aktepe et al. (2011) ¹⁷ Turkey	<u>EIA-based test:</u> Monoclonal antigen FemtoLab <i>H. pylori</i> Cnx kits (Connex GmbH, Martinsried, Germany)	Cut-off: NR	Endoscopy (culture, biopsy PCR, FISH)	Endoscopy (histopathology using giemsa and hematoxylin and eosin)	Sensitivity: 72.2% Specificity: 66.7% PPV: 81.3% NPV: 45.5%	<u>Culture</u> Sensitivity: 61.2% Specificity: 91.5% PPV: 92.9% NPV: 43.4% <u>Biopsy PCR</u> Sensitivity: 88.2% Specificity: 51.1% PPV: 76.5% NPV: 29.4% <u>FISH</u> Sensitivity: 92.9% Specificity: 95.7% PPV: 97.5% NPV: 11.8%

Study	Stool antigen test	Cut-off value	Comparators	Reference standard	Test performance	
					Stool antigen test	Comparators
Authors' conclusions: "The HpSA test is a rapid, simple, and noninvasive test for monitoring therapy. FISH is an accurate, rapid, cost-effective, and easy-to-use test for <i>H. pylori</i> detection."						
Ceken et al. (2011) ¹⁸ Turkey	<u>ICA-based test:</u> Monoclonal Helicobacter antigen Quick Castle test kit (GENERIC ASSAYS GmbH, Germany)	Cut-off: NR	Endoscopy (rapid urease test)	Endoscopy (histopathology)	Sensitivity: 68.9% Specificity: 100% PPV: 100% NPV: 67.2% Accuracy: 81%	<u>Rapid urease test</u> Sensitivity: 62.2% Specificity: 100% PPV: 100% NPV: 66.1% Accuracy: 80%
Authors' conclusions: "The results obtained with biopsy urease and HpSA tests were generally similar to those obtained by histopathological examination."						
Choi et al. (2011) ¹⁹ South Korea	<u>EIA-based using polyclonal antibodies</u> EZ-STEP <i>H. pylori</i>	Cut-off: 0.160	Endoscopy (rapid urease test) Urea breath test	At least two of four tests (histology, rapid urease test, ¹³ C-urea breath test, and serology) were positive	Sensitivity: 93.1% Specificity: 94.6% PPV: 95.1% NPV: 92.3% Accuracy: 93.8%	<u>Histology</u> Sensitivity: 89.1% Specificity: 98.8% PPV: 98.8% NPV: 88.8% Accuracy: 93.6% <u>Rapid urease test</u> Sensitivity: 91.2% Specificity: 99.6% PPV: 99.6% NPV: 90.9% Accuracy: 95.1% <u>Urea breath test</u> Sensitivity: 92.7% Specificity: 99.6% PPV: 99.6% NPV: 92.3% Accuracy: 95.9%
Authors' conclusions: "The performance of a new stool antigen test was comparable to that of other methods in the diagnosis of <i>H. pylori</i> infection for the screening population, even with the presence of atrophic gastritis/intestinal metaplasia."						
Kazemi et al. (2011) ²⁰ Iran	<u>ICA-based test:</u> Monoclonal GENERIC ASSAYS GmbH,	Cut-off: NR	Endoscopy (rapid urease test)	At least two of five tests (stool antigen test, urea breath test, rapid urease test, serology and	Sensitivity: 96% Specificity: 83% PPV: 98% NPV: 96%	<u>Histology</u> Sensitivity: 89% Specificity: 78% PPV: 93%

Study	Stool antigen test	Cut-off value	Comparators	Reference standard	Test performance	
					Stool antigen test	Comparators
	Germany)		Urea breath test	histology) were positive	Accuracy: 91%	NPV: 91% Accuracy: 85% <u>Rapid urease test</u> Sensitivity: 93% Specificity: 75% PPV: 95% NPV: 94% Accuracy: 86% <u>Urea breath test</u> Sensitivity: 96% Specificity: 83% PPV: 98% NPV: 96% Accuracy: 91%
Authors' conclusions: "Stool antigen test is the most accurate test for <i>Helicobacter pylori</i> diagnosis before eradication of these bacteria."						
Kesli et al. (2010) ²¹ Turkey	<u>EIA-based tests:</u> Monoclonal Premier Platinum HpSA Plus (Meridian Bioscience, Inc, cincinnati, OH) Hp Ag (Dia.Pro Diagnostic Bioprobes Srl, Milano, Italy)	Cut-off: 0.100	<u>Lateral flow chromatography (ICA)</u> Polyclonal <i>H. pylori</i> fecal antigen test (Vegal Farmaceutical, Madrid, Spain)	Endoscopy (histopathology and rapid urease test)	<u>Premier Platinum HpSA Plus</u> Sensitivity: 90% Specificity: 91% PPV: 85% NPV: 94% Accuracy: 90% <u>Hp Ag</u> Sensitivity: 77% Specificity: 91% PPV: 83% NPV: 87% Accuracy: 86%	<u>H.pylori fecal antigen test</u> Sensitivity: 81% Specificity: 92% PPV: 86% NPV: 89% Accuracy: 88%
Authors' conclusions: "One of the 2 important conclusions obtained from the study was that the Premier Platinum HpSA Plus was found to be the most accurate test for the diagnosis of <i>H. pylori</i> infection in adult dyspeptic patients before eradication therapy, and the other was that monoclonal and high-quality, reliable immunochromatographic assay tests are a good option especially for small hospital laboratories that do not have appropriate equipment for performing the EIA and working on few samples."						
Silva et al. (2010) ²²	<u>ICA-based test:</u> Monoclonal One step <i>H. pylori</i>	Cut-off: NR	none	¹³ C-urea breath test	Sensitivity: 88% Specificity: 87.5% PPV: 88%	none

Study	Stool antigen test	Cut-off value	Comparators	Reference standard	Test performance	
					Stool antigen test	Comparators
Brazil	antigen test device, IHP-602, ACON laboratories, Inc, San Diego, USA; Prime diagnostics, Sao Paulo, Brazil				NPV: 87.5%	
Authors' conclusions: "the lateral flow stool antigen test can be used as an alternative to breath test for <i>H. pylori</i> infection diagnosis especially in developing countries."						
Calvet et al. (2009) ²³ Spain	EIA-based test: Monoclonal EIA (Amplified IDEIA Hp StAR [Thermo Fisher Scientific])	Cut-off: 0.150	Endoscopy (histology, rapid urease test) Urea breath test	At least two of four tests (histology, rapid urease test, ¹³ C-urea breath test, and fecal test) were positive	Sensitivity: 90.3% Specificity: 93% PPV: 94.4% NPV: 87.9%	<u>Histology</u> Sensitivity: 93.8% Specificity: 98.8% PPV: 99.1% NPV: 92.4% <u>Rapid urease test</u> Sensitivity: 94.7% Specificity: 100% PPV: 100% NPV: 93.5% <u>Urea breath test</u> Sensitivity: 90.3% Specificity: 89.5% PPV: 91.9% NPV: 87.5%
Authors' conclusions: "Histological examination and rapid urease testing showed excellent diagnostic reliability. The stool test seems to be a good, noninvasive alternative to endoscopy-based tests. By contrast, the infrared-based UBT evaluated in our study showed a lower than expected performance, which was partially corrected when the cut-off value for the test was recalculated."						
Fecal antigen detection studies (for follow-up testing)						
Shimoyama et al. (2011) ²⁴ Japan	<u>EIA-based test:</u> Monoclonal EIA: Testmate rapid pylori antigen (Rapid TPAg; Wakamoto Pharmaceutical	Cut-off: NR	Urea breath test	Endoscopy (histopathology)	Agreement: 94.1% Accuracy: 98.0%	Agreement: 94.1% Accuracy: 96.0%

Study	Stool antigen test	Cut-off value	Comparators	Reference standard	Test performance	
					Stool antigen test	Comparators
	Co., Ltd, Kanagawa, Japan)					
Authors' conclusions: "Rapid TPAg is a useful diagnostic test for immediate and accurate determination of the results of H. pylori eradication therapy. The antigenicity of stool sample suspensions was preserved for 7 days in the collection devices."						
Calvet et al. (2010) ²⁵ Spain	<u>EIA-based test:</u> Monoclonal Amplified IDEIA Hp StAR	Cut-off: 0.150	<u>ICA-based tests</u> (monoclonal): • RAPID Hp StAR • ImmunoCard STAT! HpSA	Endoscopy (histopathology) or urea breath test	Sensitivity: 100% Specificity: 93.6% PPV: 66.7% NPV: 100%	<u>RAPID Hp StAR</u> Sensitivity: 100% Specificity: 93.6% PPV: 67.0% NPV: 100% <u>ImmunoCard STAT! HpSA</u> Sensitivity: 90% Specificity: 94.9% PPV: 69.2% NPV: 98.7%
Authors' conclusions: "All monoclonal fecal tests in this series presented similar performance in the post-treatment setting. A negative test after treatment predicted cure of the infection. However, nearly a third of tests were false positive, showing a poor predictive yield for persistent infection."						
Falaknazi et al. (2010) ²⁶ Iran	<u>EIA-based test using polyclonal antibodies:</u> Premier Platinum HpSA (Astra SRL, Via Ciro Menotti, Milano, Italy)	Cut-off: 0.12	none	<u>Gold for diagnosis</u> At least two of three tests (serology, ¹³ C-urea breath test, and fecal test) were positive <u>Gold for follow-up testing</u> Urea breath test	<u>Diagnosis</u> Sensitivity: 87.1% Specificity: 93.7% PPV: 91.8% NPV: 90.0% <u>After treatment to detect failure of eradication</u> Sensitivity: 42.8% Specificity: 93.3% PPV: 60.0% NPV: 87.5%	none
Authors' conclusions: "Helicobacter pylori stool antigen assay is a noninvasive reliable tool to screen H pylori infection before therapy and assess the success of eradication in patients on hemodialysis."						
Shimoyama et al. (2010) ²⁷ Japan	<u>EIA-based tests:</u> • TPAg EIA • HpSA ELISA II	Cut-off: NR	none	Urea breath test	Agreement between the two tests: 95.6% Agreement to urea	none

Study	Stool antigen test	Cut-off value	Comparators	Reference standard	Test performance	
					Stool antigen test	Comparators
					breath test: • TPAg EIA: 91.2% • HpSA ELISA II: 95.4%	
Authors' conclusions: "Both TPAg EIA and HpSA ELISA II were equally useful to determine the results of eradication therapy comparing with UBT."						
Shimoyama et al. (2009) ²⁸ Japan	<u>EIA-based test:</u> TPAg EIA (monoclonal)	Cut-off: NR	none	Urea breath test	Agreement to urea breath test: 94.7%	none
Authors' conclusions: "TPAg appears to be an accurate test for evaluating the results of H. pylori eradication therapy, and to be as efficient as ¹³ C-UBT."						
Degichi et al. (2009) ²⁹ Japan	<u>EIA-based tests:</u> • Testmate H. pylori antigen EIA (monoclonal) • HpSA (polyclonal)	Monoclonal Cut-off: 0.100 Polyclonal Cut-off: <0.100 negative, >0.120 positive, 0.100 to 0.119 equivocal	none	Urea breath test	<u>Monoclonal (Testmate)</u> Sensitivity: 91.6% Specificity: 98.4% <u>Polyclonal (HpSA)</u> Sensitivity: 87.0% Specificity: 97.5%	none
Authors' conclusions: "The new stool antigen test using monoclonal antibody is useful for the diagnosis of H. pylori eradication 4 weeks after the end of treatment."						
EIA = enzyme immunoassay; FISH = fluorescence <i>in situ</i> hybridization; ICA = immunochromatographic assay; NPV = negative predictive value; NR = not reported; PCR = polymerase chain reaction; PPV = positive predictive value; SD = standard deviation						

APPENDIX 9: Main Study Findings and Authors' Conclusions – Economic

Author, Year, Country	Main Study Findings																																																																
Schulz et al. (2014) ³¹ Australia	<p>Net cost per cancer prevented (US\$) for each strategy at varying prevalence of <i>H. pylori</i></p> <table border="1" data-bbox="418 415 1424 919"> <thead> <tr> <th data-bbox="418 415 959 447">Net cost per cancer prevented</th> <th colspan="3" data-bbox="1122 415 1424 447">Prevalence</th> </tr> <tr> <th data-bbox="418 447 959 478">Management options</th> <th data-bbox="967 447 1114 478">25%</th> <th data-bbox="1122 447 1268 478">50%</th> <th data-bbox="1276 447 1424 478">75%</th> </tr> </thead> <tbody> <tr> <td data-bbox="418 478 959 510">Treat all and no screening</td> <td data-bbox="967 478 1114 510">477800</td> <td data-bbox="1122 478 1268 510">206900</td> <td data-bbox="1276 478 1424 510">116600</td> </tr> <tr> <td data-bbox="418 510 959 541">Serology</td> <td></td> <td></td> <td></td> </tr> <tr> <td data-bbox="418 541 959 573"> No follow-up</td> <td data-bbox="967 541 1114 573">294700</td> <td data-bbox="1122 541 1268 573">169900</td> <td data-bbox="1276 541 1424 573">128300</td> </tr> <tr> <td data-bbox="418 573 959 604">Stool antigen test</td> <td></td> <td></td> <td></td> </tr> <tr> <td data-bbox="418 604 959 636"> No follow-up</td> <td data-bbox="967 604 1114 636">219200</td> <td data-bbox="1122 604 1268 636">142700</td> <td data-bbox="1276 604 1424 636">117100</td> </tr> <tr> <td data-bbox="418 636 959 667"> Follow-up and retreat</td> <td data-bbox="967 636 1114 667">193900</td> <td data-bbox="1122 636 1268 667">132300</td> <td data-bbox="1276 636 1424 667">111800</td> </tr> <tr> <td data-bbox="418 667 959 699">Urea breath test</td> <td></td> <td></td> <td></td> </tr> <tr> <td data-bbox="418 699 959 730"> No follow-up</td> <td data-bbox="967 699 1114 730">360200</td> <td data-bbox="1122 699 1268 730">213800</td> <td data-bbox="1276 699 1424 730">165000</td> </tr> <tr> <td data-bbox="418 730 959 762"> Follow-up and retreat</td> <td data-bbox="967 730 1114 762">334600</td> <td data-bbox="1122 730 1268 762">216400</td> <td data-bbox="1276 730 1424 762">177000</td> </tr> <tr> <td data-bbox="418 762 959 793">Gastroscopy</td> <td></td> <td></td> <td></td> </tr> <tr> <td data-bbox="418 793 959 825"> No follow-up</td> <td data-bbox="967 793 1114 825">972000</td> <td data-bbox="1122 793 1268 825">520600</td> <td data-bbox="1276 793 1424 825">370200</td> </tr> <tr> <td data-bbox="418 825 959 856"> Follow-up with gastroscopy and retreat</td> <td data-bbox="967 825 1114 856">939900</td> <td data-bbox="1122 825 1268 856">577200</td> <td data-bbox="1276 825 1424 856">456300</td> </tr> <tr> <td data-bbox="418 856 959 888"> Follow-up with breath test and retreat</td> <td data-bbox="967 856 1114 888">820200</td> <td data-bbox="1122 856 1268 888">460100</td> <td data-bbox="1276 856 1424 888">340100</td> </tr> <tr> <td data-bbox="418 888 959 919"> Follow-up with stool antigen and retreat</td> <td data-bbox="967 888 1114 919">794400</td> <td data-bbox="1122 888 1268 919">433900</td> <td data-bbox="1276 888 1424 919">313700</td> </tr> </tbody> </table> <p>Authors' conclusions: "<i>H. pylori</i> screening and eradication can be effective strategy for reducing rates of gastric cancer and peptic ulcers in high prevalence populations and our data suggest that use of stool antigen testing is the most cost effective approach."</p>	Net cost per cancer prevented	Prevalence			Management options	25%	50%	75%	Treat all and no screening	477800	206900	116600	Serology				No follow-up	294700	169900	128300	Stool antigen test				No follow-up	219200	142700	117100	Follow-up and retreat	193900	132300	111800	Urea breath test				No follow-up	360200	213800	165000	Follow-up and retreat	334600	216400	177000	Gastroscopy				No follow-up	972000	520600	370200	Follow-up with gastroscopy and retreat	939900	577200	456300	Follow-up with breath test and retreat	820200	460100	340100	Follow-up with stool antigen and retreat	794400	433900	313700
Net cost per cancer prevented	Prevalence																																																																
Management options	25%	50%	75%																																																														
Treat all and no screening	477800	206900	116600																																																														
Serology																																																																	
No follow-up	294700	169900	128300																																																														
Stool antigen test																																																																	
No follow-up	219200	142700	117100																																																														
Follow-up and retreat	193900	132300	111800																																																														
Urea breath test																																																																	
No follow-up	360200	213800	165000																																																														
Follow-up and retreat	334600	216400	177000																																																														
Gastroscopy																																																																	
No follow-up	972000	520600	370200																																																														
Follow-up with gastroscopy and retreat	939900	577200	456300																																																														
Follow-up with breath test and retreat	820200	460100	340100																																																														
Follow-up with stool antigen and retreat	794400	433900	313700																																																														
Holmes et al. (2010) ³⁰ USA	<p>Cost-effectiveness ratios for each strategy</p> <table border="1" data-bbox="418 1045 1239 1329"> <thead> <tr> <th data-bbox="418 1045 865 1108">Strategy</th> <th data-bbox="873 1045 1239 1108">Cost (US\$) per symptom-free year (95% CI)</th> </tr> </thead> <tbody> <tr> <td data-bbox="418 1108 865 1140">PPI therapy</td> <td data-bbox="873 1108 1239 1140">122.13 (120.00 to 124.88)</td> </tr> <tr> <td data-bbox="418 1140 865 1171">Stool antigen</td> <td data-bbox="873 1140 1239 1171">123.23 (120.68 to 125.58)</td> </tr> <tr> <td data-bbox="418 1171 865 1203">IgG serology</td> <td data-bbox="873 1171 1239 1203">125.76 (123.18 to 128.27)</td> </tr> <tr> <td data-bbox="418 1203 865 1266">IgG serology with reflex to stool antigen</td> <td data-bbox="873 1203 1239 1266">126.17 (123.43 to 128.08)</td> </tr> <tr> <td data-bbox="418 1266 865 1297">Urea breath test</td> <td data-bbox="873 1266 1239 1297">128.31 (125.69 to 130.72)</td> </tr> <tr> <td data-bbox="418 1297 865 1329">IgG/IgA binary serology</td> <td data-bbox="873 1297 1239 1329">129.04 (126.43 to 131.48)</td> </tr> </tbody> </table> <p>Cost per correct diagnosis for each strategy modeled</p> <table border="1" data-bbox="418 1392 1239 1644"> <thead> <tr> <th data-bbox="418 1392 865 1455">Testing strategy</th> <th data-bbox="873 1392 1239 1455">Average cost per correct diagnosis</th> </tr> </thead> <tbody> <tr> <td data-bbox="418 1455 865 1486">Stool antigen</td> <td data-bbox="873 1455 1239 1486">\$2767.85</td> </tr> <tr> <td data-bbox="418 1486 865 1518">Urea breath test</td> <td data-bbox="873 1486 1239 1518">\$2825.24</td> </tr> <tr> <td data-bbox="418 1518 865 1549">IgG serology</td> <td data-bbox="873 1518 1239 1549">\$3371.91</td> </tr> <tr> <td data-bbox="418 1549 865 1612">IgG serology with reflex to stool antigen</td> <td data-bbox="873 1549 1239 1612">\$3373.39</td> </tr> <tr> <td data-bbox="418 1612 865 1644">IgG/IgA binary serology</td> <td data-bbox="873 1612 1239 1644">\$4061.91</td> </tr> </tbody> </table> <p>None of the results were sensitive to changes in prevalence of <i>H. pylori</i> (5% to 40%).</p>	Strategy	Cost (US\$) per symptom-free year (95% CI)	PPI therapy	122.13 (120.00 to 124.88)	Stool antigen	123.23 (120.68 to 125.58)	IgG serology	125.76 (123.18 to 128.27)	IgG serology with reflex to stool antigen	126.17 (123.43 to 128.08)	Urea breath test	128.31 (125.69 to 130.72)	IgG/IgA binary serology	129.04 (126.43 to 131.48)	Testing strategy	Average cost per correct diagnosis	Stool antigen	\$2767.85	Urea breath test	\$2825.24	IgG serology	\$3371.91	IgG serology with reflex to stool antigen	\$3373.39	IgG/IgA binary serology	\$4061.91																																						
Strategy	Cost (US\$) per symptom-free year (95% CI)																																																																
PPI therapy	122.13 (120.00 to 124.88)																																																																
Stool antigen	123.23 (120.68 to 125.58)																																																																
IgG serology	125.76 (123.18 to 128.27)																																																																
IgG serology with reflex to stool antigen	126.17 (123.43 to 128.08)																																																																
Urea breath test	128.31 (125.69 to 130.72)																																																																
IgG/IgA binary serology	129.04 (126.43 to 131.48)																																																																
Testing strategy	Average cost per correct diagnosis																																																																
Stool antigen	\$2767.85																																																																
Urea breath test	\$2825.24																																																																
IgG serology	\$3371.91																																																																
IgG serology with reflex to stool antigen	\$3373.39																																																																
IgG/IgA binary serology	\$4061.91																																																																
	<p>Authors' conclusions: "<i>In this model of H. pylori</i> diagnosis and treatment, the choice of initial noninvasive test did not have a significant impact on cost or quality outcome. This is likely attributable to the assumption of a high resource intensity practice environment. In practice settings where endoscopy is less available and/or less readily employed, these findings may not apply."</p> <p>IgA = immunoglobulin; IgG = immunoglobulin G; PPI = proton pump inhibitor</p>																																																																

APPENDIX 10: Guidelines and Recommendations on stool antigen tests for *Helicobacter pylori* infection

Guideline Society, Country, Author, Year	Recommendations
European Helicobacter Study Group Malfertheiner et al. (2012) ³² 44 experts, 24 countries	<ul style="list-style-type: none"> • <i>The main non-invasive tests that can be used for the test-and-treat strategy are the UBT and monoclonal stool antigen tests. Certain validated serological tests can also be used. (Grade B, Level 2a) p. 647</i> • <i>The diagnostic accuracy of the stool antigen (SAT) is equivalent to the UBT if a validated laboratory-based monoclonal test is used. (Grade A, Level 1a) p. 649</i> • <i>The UBT or a laboratory-based validated monoclonal stool test are both recommended as non-invasive tests for determining the success of eradication treatment. There is no role for serology. (Grade A, Level 1a) p. 653</i>
UBT = urea breath test	